Fungal Infections

November 5th 2024

ActivePure’s Deborah Birx, MD, and Amy Carenza, BBA, discuss their study showing a 99% reduction in fungal colony-forming units, 98% reduction in aerobic bacteria, and a 66% decrease in C auris.

October 31st 2024

This systematic review focuses on breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological cancers, like acute leukemia, or those who have undergone stem cell transplants. Despite prophylactic antifungal treatments (usually with voriconazole or posaconazole), bIFIs remain challenging due to their complexity and high mortality rates.

October 7th 2024

Basilea Pharmaceutica says its investigational therapy, fosmanogepix, is being studied for candidemia and invasive candidiasis.

September 25th 2024

In the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.